| pubmed-article:1676427 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1676427 | lifeskim:mentions | umls-concept:C0035647 | lld:lifeskim |
| pubmed-article:1676427 | lifeskim:mentions | umls-concept:C0040615 | lld:lifeskim |
| pubmed-article:1676427 | lifeskim:mentions | umls-concept:C1276996 | lld:lifeskim |
| pubmed-article:1676427 | lifeskim:mentions | umls-concept:C0044097 | lld:lifeskim |
| pubmed-article:1676427 | lifeskim:mentions | umls-concept:C0243072 | lld:lifeskim |
| pubmed-article:1676427 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:1676427 | pubmed:dateCreated | 1991-8-6 | lld:pubmed |
| pubmed-article:1676427 | pubmed:abstractText | The design and synthesis of a series of potential atypical antipsychotic agents based on the structure of 1-naphthylpiperazine are described. The incorporation of dopamine antagonist activity into the parent structure was achieved with heterocyclic surrogates for the catechol moiety of dopamine. Compound 4b from this series showed a biochemical profile that translated to behavioral activity in the rat predictive of an antipsychotic agent with a low propensity to cause extrapyramidal side effects in man. | lld:pubmed |
| pubmed-article:1676427 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1676427 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1676427 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1676427 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1676427 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1676427 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1676427 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1676427 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1676427 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1676427 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1676427 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1676427 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1676427 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1676427 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1676427 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1676427 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:1676427 | pubmed:issn | 0022-2623 | lld:pubmed |
| pubmed-article:1676427 | pubmed:author | pubmed-author:EwingF EFE | lld:pubmed |
| pubmed-article:1676427 | pubmed:author | pubmed-author:SeegerT FTF | lld:pubmed |
| pubmed-article:1676427 | pubmed:author | pubmed-author:NewmanM EME | lld:pubmed |
| pubmed-article:1676427 | pubmed:author | pubmed-author:HowardH RHR | lld:pubmed |
| pubmed-article:1676427 | pubmed:author | pubmed-author:SchmidtA WAW | lld:pubmed |
| pubmed-article:1676427 | pubmed:author | pubmed-author:LoweJ AJA3rd | lld:pubmed |
| pubmed-article:1676427 | pubmed:author | pubmed-author:NagelA AAA | lld:pubmed |
| pubmed-article:1676427 | pubmed:author | pubmed-author:SeymourP APA | lld:pubmed |
| pubmed-article:1676427 | pubmed:author | pubmed-author:HeymJ HJH | lld:pubmed |
| pubmed-article:1676427 | pubmed:author | pubmed-author:FurmanJ SJS | lld:pubmed |
| pubmed-article:1676427 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1676427 | pubmed:volume | 34 | lld:pubmed |
| pubmed-article:1676427 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1676427 | pubmed:authorsComplete | N | lld:pubmed |
| pubmed-article:1676427 | pubmed:pagination | 1860-6 | lld:pubmed |
| pubmed-article:1676427 | pubmed:dateRevised | 2003-11-14 | lld:pubmed |
| pubmed-article:1676427 | pubmed:meshHeading | pubmed-meshheading:1676427-... | lld:pubmed |
| pubmed-article:1676427 | pubmed:meshHeading | pubmed-meshheading:1676427-... | lld:pubmed |
| pubmed-article:1676427 | pubmed:meshHeading | pubmed-meshheading:1676427-... | lld:pubmed |
| pubmed-article:1676427 | pubmed:meshHeading | pubmed-meshheading:1676427-... | lld:pubmed |
| pubmed-article:1676427 | pubmed:meshHeading | pubmed-meshheading:1676427-... | lld:pubmed |
| pubmed-article:1676427 | pubmed:meshHeading | pubmed-meshheading:1676427-... | lld:pubmed |
| pubmed-article:1676427 | pubmed:meshHeading | pubmed-meshheading:1676427-... | lld:pubmed |
| pubmed-article:1676427 | pubmed:meshHeading | pubmed-meshheading:1676427-... | lld:pubmed |
| pubmed-article:1676427 | pubmed:meshHeading | pubmed-meshheading:1676427-... | lld:pubmed |
| pubmed-article:1676427 | pubmed:meshHeading | pubmed-meshheading:1676427-... | lld:pubmed |
| pubmed-article:1676427 | pubmed:meshHeading | pubmed-meshheading:1676427-... | lld:pubmed |
| pubmed-article:1676427 | pubmed:meshHeading | pubmed-meshheading:1676427-... | lld:pubmed |
| pubmed-article:1676427 | pubmed:meshHeading | pubmed-meshheading:1676427-... | lld:pubmed |
| pubmed-article:1676427 | pubmed:meshHeading | pubmed-meshheading:1676427-... | lld:pubmed |
| pubmed-article:1676427 | pubmed:meshHeading | pubmed-meshheading:1676427-... | lld:pubmed |
| pubmed-article:1676427 | pubmed:meshHeading | pubmed-meshheading:1676427-... | lld:pubmed |
| pubmed-article:1676427 | pubmed:meshHeading | pubmed-meshheading:1676427-... | lld:pubmed |
| pubmed-article:1676427 | pubmed:meshHeading | pubmed-meshheading:1676427-... | lld:pubmed |
| pubmed-article:1676427 | pubmed:year | 1991 | lld:pubmed |
| pubmed-article:1676427 | pubmed:articleTitle | 1-Naphthylpiperazine derivatives as potential atypical antipsychotic agents. | lld:pubmed |
| pubmed-article:1676427 | pubmed:affiliation | Central Research Division, Pfizer, Inc., Groton, Connecticut 06340. | lld:pubmed |
| pubmed-article:1676427 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:1676427 | lld:chembl |
